Thomas G. Martin, MD
University of California SF
San Francisco, California, USA

A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma

Abstract No: 8512

Background: SAR650984 (SAR) is a humanized IgG1 monoclonal antibody that binds selectively to a unique epitope on human CD38 receptor. SAR kills tumor cells via antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, direct apoptosis induction without secondary crosslinking and allosteric inhibition on CD38 enzymatic activity. We present data on the dose escalation phase of the study (NCT01749969).

Methods: Three dose levels (DL) of SAR 3, 5 and 10 mg/kg were evaluated in combination with lenalidomide (LEN) and dexamethasone (Dex). LEN 25 mg was given on days (d) 1 – 21 and D 40 mg on d 1, 8, 15 and 22 every 28 d’s. SAR was given IV on d 1 and 15 and escalated using the classic 3+3 design.

Results: 13 patients (pts) with RRMM were treated; median age 61 yrs (48 - 73); median prior treatment regimens 6 (2 - 12), 100% had received prior LEN (23% prior pomalidomide) and 92.3% previously received bortezomib (38.5% prior carfilzomib). The median time from diagnosis to first SAR dosing was 4.5 yrs (3 - 11). The maximum tolerated dose was not reached. The most frequent adverse events included nausea, cough (n = 6 each); fatigue, muscle spasm, infection (n = 5 each); vomiting, diarrhea, dehydration and insomnia (n = 4 each). Grade (G) ≥ 3 hematologic abnormalities were neutropenia (n = 4) and thrombocytopenia (n = 3). One pt discontinued therapy (cycle 1, d 1) due to an infusion reaction (bronchospasm G 3). The ORR (≥ PR), according to IMWG criteria, among 12 evaluable pts was 58 %. Responses occurred at each DL of 3mg/kg (1PR), 5mg/kg (1PR, 1 VGPR) and 10 mg/kg (1PR, 3 VGPR). Clinical benefit response (≥ MR) was 67 % with 1 MR at 3 mg/kg. Median time on treatment was 20.6 weeks (0 - 35) and 7 pts remain on therapy. PK showed non linearity at select dose levels, SAR plasma trough levels were above target for tumor eradication from preclinical data.

Conclusions: The combination of SAR with LEN/Dex was tolerated and no DLT’s were reported at any DL. SAR + LEN/Dex demonstrated encouraging efficacy in pts with heavily pretreated RRMM. An expansion cohort of 18 pts recently enrolled on the trial and the results will be reported at the meeting.

Clinical trial information: NCT01749969.

Author(s): Thomas G. Martin, Karl Hsu, Eric Charpentier, Ravi Vij, Rachid C. Baz, Don M. Benson, Nikoletta Lendvai; University of San Francisco, San Francisco, CA; Sanofi-Aventis, Cambridge, MA; Multiple Myeloma Research Consortium, Norwalk, CT/Washington University School of Medicine, St. Louis, MO; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University, Columbus, OH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Download PDF

 


ABOUT THOMAS G. MARTIN, MD

A leading expert in hematology-oncology, Dr. Thomas Martin is the Associate Director of UCSF's Myeloma Program and Director of the Unrelated Donor Transplantation Programs for Adults at UCSF Medical Center. Dr. Martin is the Clinical Research Director of Hematologic Malignancies (blood cancers) at the UCSF Helen Diller Family Comprehensive Cancer Center.. Visit Dr. Thomas G. Martin’s full biography.

Previous Post
ASCO 2014: A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory MM
Next Post
ASCO 2014: Results of CHAMPION-1 investigating weekly carfilzomib in combination with dex for R/R MM

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.